Hanall Biopharma (009420) — Cash Flow-to-Debt Ratio
Hanall Biopharma (009420) has a Cash Flow-to-Debt Ratio of 0.17x as of September 2025, meaning its operating cash flow of ₩7.34 Billion could theoretically repay 0% of its total liabilities (₩44.17 Billion) in one year. Explore investment intensity of Hanall Biopharma to see how much of total assets are deployed in long-term investments.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Hanall Biopharma Cash Flow-to-Debt Ratio (2011–2024)
Historical debt coverage capacity for Hanall Biopharma across 14 annual periods. Also explore 009420 total asset value for the complete picture of this company's asset base.
Annual Cash Flow-to-Debt Ratio for Hanall Biopharma (2011–2024)
Year-by-year debt coverage analysis for Hanall Biopharma. For market capitalisation and broader financial context, see Hanall Biopharma stock valuation.
| Year | CF-to-Debt Ratio | Operating CF (KRW) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | 0.21x | ₩9.36 Billion | ₩44.53 Billion | ▼ -62.0% |
| 2023 | 0.55x | ₩29.64 Billion | ₩53.53 Billion | ▼ -0.7% |
| 2022 | 0.56x | ₩25.20 Billion | ₩45.19 Billion | ▲ +2223.1% |
| 2021 | 0.02x | ₩839.87 Million | ₩34.99 Billion | ▲ +0.4% |
| 2020 | 0.02x | ₩929.29 Million | ₩38.86 Billion | ▼ -94.1% |
| 2019 | 0.40x | ₩20.49 Billion | ₩50.97 Billion | ▲ +709.4% |
| 2018 | -0.07x | ₩-2.99 Billion | ₩45.39 Billion | ▼ -109.0% |
| 2017 | 0.73x | ₩42.14 Billion | ₩57.50 Billion | ▲ +278.0% |
| 2016 | 0.19x | ₩3.95 Billion | ₩20.37 Billion | ▲ +1035.7% |
| 2015 | -0.02x | ₩-454.02 Million | ₩21.91 Billion | ▲ +75.6% |
| 2014 | -0.09x | ₩-3.52 Billion | ₩41.36 Billion | ▲ +58.2% |
| 2013 | -0.20x | ₩-7.78 Billion | ₩38.23 Billion | ▼ -522.4% |
| 2012 | 0.05x | ₩2.20 Billion | ₩45.60 Billion | ▼ -64.4% |
| 2011 | 0.14x | ₩7.41 Billion | ₩54.75 Billion | — |